Papadopoulou-Marketou Nektaria, Papageorgiou Anna, Marketos Nikolaos, Tsiamyrtzis Panagiotis, Vavetsis Georgios, Chrousos George P
Neuroendocrine Tumor Unit, ENETS Centre of Excellence, 1st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
University Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens, Athens 11527, Greece.
J Clin Endocrinol Metab. 2025 Aug 7;110(9):e2878-e2887. doi: 10.1210/clinem/dgaf077.
Osteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS). Osteostrong® is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, high-intensity osteogenic loading exercises. The aim of this study was to assess changes in BMD and TBS in the lumbar spine and/or hip over 12 months in peri-/post menopausal women with Osteoporosis following Osteostrong® intervention and to compare these outcomes with women who did not receive such intervention.
A quasi-experimental case-series study in which 147 participants were separated into 2 groups, following informed consent: 75 in group A receiving Osteostrong® (subgroup G1 without and G2 with antiresorptive medication); and 72 in group B without Osteostrong® (subgroup G3 without and G4 with antiresorptive medication). Changes in lumbar spine and hip BMD and/or TBS were assessed at inclusion and 12 months later. Bonferroni-adjusted non-parametric paired tests examined for significant paired mean differences within each subgroup.
After Bonferroni adjustment, significant increases were observed in lumbar spine BMD in G2 (mean paired change: 0.029 g/cm2; Bonferroni-adjusted p < 0.001), and G4 (mean paired change: 0.025 g/cm2; Bonferroni-adjusted p = 0.05) as well as BMD-total hip left in G2 (mean paired change: 0.028 g/cm2; Bonferroni-adjusted p = 0.05). Other within-group changes in femoral neck BMD, total hip BMD, and TBS did not retain significance following Bonferroni correction.
The Osteostrong® intervention showed modest lumbar spine BMD improvements over 12 months; some subgroup effects were significant but not when Bonferroni-adjusted, warranting cautious interpretation and further randomized trials.
骨质疏松症的特征是骨矿物质密度（BMD）降低以及通过小梁骨评分（TBS）评估的微结构破坏。Osteostrong®是一种骨骼强化系统，配备4种设备，并纳入了简短（10分钟）、每周一次、低冲击、高强度的成骨负荷运动。本研究的目的是评估接受Osteostrong®干预的绝经前后骨质疏松症女性在12个月内腰椎和/或髋部BMD和TBS的变化，并将这些结果与未接受此类干预的女性进行比较。
一项准实验性病例系列研究，147名参与者在获得知情同意后被分为2组：A组75人接受Osteostrong®（G1亚组未使用抗吸收药物，G2亚组使用抗吸收药物）；B组72人未接受Osteostrong®（G3亚组未使用抗吸收药物，G4亚组使用抗吸收药物）。在纳入时和12个月后评估腰椎和髋部BMD和/或TBS的变化。采用Bonferroni校正的非参数配对检验来检验每个亚组内配对均值的显著差异。
经过Bonferroni校正后，G2组腰椎BMD有显著增加（平均配对变化：0.029 g/cm²；Bonferroni校正p < 0.001），G4组也有显著增加（平均配对变化：0.025 g/cm²；Bonferroni校正p = 0.05）；G2组左侧全髋部BMD也有显著增加（平均配对变化：0.028 g/cm²；Bonferroni校正p = 0.05）。在Bonferroni校正后，股骨颈BMD、全髋部BMD和TBS的其他组内变化不再具有显著性。
Osteostrong®干预在12个月内使腰椎BMD有适度改善；一些亚组效应显著，但经Bonferroni校正后则不然，这需要谨慎解读并进行进一步的随机试验。
